What is Wedbush’s Estimate for ORKA FY2029 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Analysts at Wedbush issued their FY2029 earnings estimates for shares of Oruka Therapeutics in a report released on Wednesday, May 14th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($4.14) for the year. Wedbush currently has a “Outperform” rating and a $40.00 price objective on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17.

Several other research firms have also weighed in on ORKA. Wolfe Research began coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $39.86.

Oruka Therapeutics Trading Up 6.3%

NASDAQ:ORKA opened at $10.06 on Friday. The firm has a market capitalization of $376.66 million, a price-to-earnings ratio of -1.61 and a beta of 0.25. The firm’s fifty day simple moving average is $9.86 and its 200 day simple moving average is $14.77. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new stake in Oruka Therapeutics during the 1st quarter worth $2,505,000. ADAR1 Capital Management LLC purchased a new stake in Oruka Therapeutics during the 1st quarter worth $1,362,000. Braidwell LP increased its stake in Oruka Therapeutics by 37.0% during the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock worth $16,133,000 after buying an additional 424,750 shares during the period. OMERS ADMINISTRATION Corp increased its stake in Oruka Therapeutics by 126.8% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company’s stock worth $461,000 after buying an additional 25,100 shares during the period. Finally, Affinity Asset Advisors LLC increased its stake in Oruka Therapeutics by 47.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock worth $5,595,000 after buying an additional 176,664 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.